I am a healthcare professional

Notice


Welcome to MEDICALLY. This website is a non-promotional international resource intended to facilitate transparent scientific exchange regarding developments in medical research and disease management. It is intended for healthcare professionals outside the United Kingdom (UK) and Australia. The content on this website may include scientific information about experimental or investigational compounds, indications and services that are not approved or valid in your jurisdiction. Registration status and prescribing information of medicinal products may differ between countries. Roche and Genentech do not support, endorse or recommend the unapproved use of any compound or service in your jurisdiction, including those discussed on this website.


Please refer to local product information for any medicinal products mentioned. Information available on this website does not constitute professional medical advice, and Roche and Genentech accept no responsibility for access to or use of the same. Healthcare professionals outside the US are required to register and log-in to access the full range of content available on this website.


By clicking on one of the healthcare professional buttons below, you acknowledge you have read and understood this message and that you are requesting access to MEDICALLY. If you are not a healthcare professional, please use the other links below to access information relevant to you.


Cookies


We use cookies on this site to enable the site to function properly and to enhance your user experience. Cookies are files stored in your browser, which most websites use to personalize your web experience. Your information will only be used to provide information that is relevant to you. It will not be used for any other purpose. If you wish to restrict or block cookies, which are set on your device, then you can do this through your browser settings.


You can find out more about cookies by browsing our Privacy Policy.

 

I am a healthcare professional in Switzerland

Required field.

For healthcare professionals in Another Country browse medically.roche.com.

Not a healthcare professional? For individuals outside the US, browse Roche's patient website or roche.com. For individuals in the US, browse gene.com.

External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site
Home Neuroscience Multiple Sclerosis

Multiple sclerosis

What's new

Sign up or login to unlock the full suite of MEDICALLY features
Feb 28 / Roche and Genentech
Real-world effectiveness of first-line ocrelizumab treatment in relapsing multiple sclerosis: insights from MSBase OCR-R sub-study
Real-world evidence on the effectiveness of ocrelizumab (OCR) in treatment-naïve patients, with relapsing multiple sclerosis (MS) remains limited. Here we present data from the ongoing 5-year MSBase OCR-R sub-study, in eight countries, measuring treatment persistence, disease activity, disability progression and improvement in patients with relapsing MS treated with ocrelizumab.
Neuroscience Multiple Sclerosis ACTRIMS-FORUM-2025

Sign up or login to unlock the full suite of MEDICALLY features
Feb 28 / Roche and Genentech
Work, Healthcare Use, and Caregiver Burden in Patients With Low-to-moderate Disability over a 2-year Treatment with Ocrelizumab
Ocrelizumab has demonstrated efficacy in slowing MS progression, however, the socio-economic outcomes of this in real-world clinical practice are poorly understood. Here we present socio-economic data and healthcare-related outcomes from MuSicalE – a multicenter, non-interventional, prospective study assessing the real-world safety and effectiveness of OCR in patients with MS over a period of 4 years, across 25 countries.
Neuroscience Multiple Sclerosis ACTRIMS-FORUM-2025

Sign up or login to unlock the full suite of MEDICALLY features
Feb 28 / Roche and Genentech
Real-world adherence & persistence to ocrelizumab versus ofatumumab among pwMS over 24 months
This retrospective US cohort study compared real-world adherence to and persistence with ocrelizumab vs ofatumumab over 24 months among people with multiple sclerosis.
Neuroscience Multiple Sclerosis ACTRIMS-FORUM-2025

Sign up or login to unlock the full suite of MEDICALLY features
Feb 27 / Roche and Genentech
Fenebrutinib Maintains Low Disease Activity in Relapsing Multiple Sclerosis: Clinical, Safety and Biomarker Results From the FENopta Open-Label Extension
This analysis assessed the efficacy, safety and exploratory biomarkers, such as immunoglobulins and B cells, after fenebrutinib treatment in people with RMS enrolled int he FENopta open-label extension through Week 48.
Neuroscience Multiple Sclerosis ACTRIMS-FORUM-2025

Sign up or login to unlock the full suite of MEDICALLY features
Feb 27 / Roche and Genentech
Exposure-Response Analyses of Ocrelizumab in Patients With Relapsing Multiple Sclerosis in OPERA I and II Over 10 Years
A consistent trend of higher ocrelizumab exposure leading to deeper B-cell depletion and greater reduction in disability progression was shown in patients with relapsing multiple sclerosis in the Phase III OPERA I and OPERA II trials. Exposure-response relationships in the pooled population of OPERA I and OPERA II were analyzed over a 10-year period. Results are reported for 48-week CDP, ARR, whole and regional brain volume loss, and safety outcomes (including change in Ig levels from baseline, proportion of patients with IgG < LLN, and rates of serious infections).
Neuroscience Multiple Sclerosis ACTRIMS-FORUM-2025

Sign up or login to unlock the full suite of MEDICALLY features
Feb 27 / Roche and Genentech
Deriving an NfL Threshold Equivalent From Atellica® to Simoa® Assays in Ocrelizumab Phase 3 Trials to Assess Disease Activity Risk in RMS
This study analyzed the translatability of a defined Siemens Atellica assa threshold for prognosticating MS disease acrivity to Quanterix Simoa-measured NfL levels in historical data of people with RMS from the OPERA trials.
Neuroscience Multiple Sclerosis ACTRIMS-FORUM-2025
Treatment management Research advancements
0 results
Upcoming congresses
Access to Roche and Genentech's latest medical information
View related congresses

Ask a question or share feedback

Get in touch

This website is intended for healthcare professionals outside the United Kingdom (UK) and Australia. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website.